Multimodal Data-assisted Primary Screening for Allergic Rhinitis Based on Voice Recognition and Face Recognition

NCT06474923 | Completed DMC

• 1 other identifier: Stent-002
• Study Type: observational
• Target: 1,500
• Locations: 1 country
• Sites: 1

Brief Summary

Collect facial images and voice and audio of patients with rhinitis in the department of otolaryngology, and collect the examination results of patients with rhinitis who have received electronic fiber nasopharyngoscopy. Skin prick test to a standard panel of aeroallergens or by using the ImmunoCAP Phadiatop test for detecting immunoglobulin E antibodies against various common inhalant allergenswere detected, and a prediction model for the type of rhinitis was finally established.

Conditions

Body Image; Speech Sound Disorder

Outcome Measures

Primary Outcomes (1)

• Allergen Test Results

  Atopic status was evaluated by skin prick test to a standard panel of aeroallergens or by using the ImmunoCAP Phadiatop test (Phadia, Uppsala, Sweden) for detecting immunoglobulin E antibodies against various common inhalant allergens. Allergic rhinitis was diagnosed in patients with a positive skin prick or positive blood IgE.

  30 minutes

Study Arms (2)

AR patient

Diagnosis was made by inhalant allergen screening and blood-serology specific IgE test results according to ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines. Clinical symptoms include sneezing, runny nose, itchy nose, and pale edema of bilateral inferior turbinate when exposed to specific allergens.

Behavioral: Face image and voice audio

Non-AR patient

The final diagnosis of non-allergic rhinitis was made based on the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines and exclusion by inhalant allergen screening and blood-serology specific IgE test results.

Behavioral: Face image and voice audio

Interventions

Face image and voice audio BEHAVIORAL

Take photographs of the front, left and right side of the patient's face. Recording the patient's voice during doctor-patient communication.

AR patient; Non-AR patient

Eligibility Criteria

• Age: 8 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Initial clinical diagnosis of chronic rhinitis, able to perform a basic examination, cooperate with face photography and voice capture

You may qualify if:

• Subjects understood the purpose and procedure of the trial and signed an informed consent form, and voluntarily participated in this study;
• Subjects were initially clinically diagnosed with chronic rhinitis;
• Subjects were aged 8-80 years old, limited to Chinese nationality, and were able to perform basic examinations and cooperate with face photography and voice collection.

You may not qualify if:

• Those who received systemic immunotherapy, used systemic or local glucocorticoids as well as leukotriene receptor antagonists within one month;
• Those who suffer from immune system diseases, autoimmune diseases, allergic diseases or allergies and have a history of food allergy;
• Other serious systemic diseases, such as active tuberculosis, rheumatic heart disease, congenital heart disease, arthritis, nephritis, hypertension, psychosis, dermatitis, epilepsy and so on;
• Women during lactation and pregnancy;
• History of upper respiratory tract infection or more serious infectious diseases within three months;
• Those who are currently participating in another clinical study or have participated in another clinical study within 90 days;

Sponsors & Collaborators

• Zheng Liu: lead

Study Sites (1)

Professor of Otolaryngology-Head & Neck Surgery Vice Director Department of ENT Tongji Hospital Tongji Medical College Huazhong University of Science and Technology Affiliation: Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

Location

MeSH Terms

Conditions

Speech Sound Disorder

Condition Hierarchy (Ancestors)

Communication Disorders; Neurodevelopmental Disorders; Mental Disorders

Study Officials

• Zheng Liu, Doctor

  Tongji Hospital

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: June 14, 2024
• First Posted: June 26, 2024
• Study Start: June 1, 2024
• Primary Completion: December 31, 2024
• Study Completion: June 1, 2025
• Last Updated: September 16, 2025

Record last verified: 2025-09

Locations

CN (1)